MXPA03006605A - Esteres de indol-5-ilo del acido bencensulfonico como antagonistas del receptor 5-ht6. - Google Patents
Esteres de indol-5-ilo del acido bencensulfonico como antagonistas del receptor 5-ht6.Info
- Publication number
- MXPA03006605A MXPA03006605A MXPA03006605A MXPA03006605A MXPA03006605A MX PA03006605 A MXPA03006605 A MX PA03006605A MX PA03006605 A MXPA03006605 A MX PA03006605A MX PA03006605 A MXPA03006605 A MX PA03006605A MX PA03006605 A MXPA03006605 A MX PA03006605A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- receptor
- esters
- benzenesulfonic acid
- acid indol
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- UXIVTIPEQSXFBC-UHFFFAOYSA-N 1h-indol-5-yl benzenesulfonate Chemical class C=1C=C2NC=CC2=CC=1OS(=O)(=O)C1=CC=CC=C1 UXIVTIPEQSXFBC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26499601P | 2001-01-30 | 2001-01-30 | |
| PCT/US2002/000502 WO2002060871A2 (en) | 2001-01-30 | 2002-01-17 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03006605A true MXPA03006605A (es) | 2003-09-22 |
Family
ID=23008516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03006605A MXPA03006605A (es) | 2001-01-30 | 2002-01-17 | Esteres de indol-5-ilo del acido bencensulfonico como antagonistas del receptor 5-ht6. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7230011B2 (enExample) |
| EP (1) | EP1377580B1 (enExample) |
| JP (1) | JP2004526699A (enExample) |
| CN (1) | CN1275967C (enExample) |
| AT (1) | ATE340795T1 (enExample) |
| AU (1) | AU2002236730B2 (enExample) |
| BR (1) | BR0206595A (enExample) |
| CA (1) | CA2433351A1 (enExample) |
| DE (1) | DE60214990T2 (enExample) |
| ES (1) | ES2272667T3 (enExample) |
| MX (1) | MXPA03006605A (enExample) |
| WO (1) | WO2002060871A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2222829B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222828B1 (es) | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
| ES2222832B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222827B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222830B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ATE430752T1 (de) * | 2004-01-02 | 2009-05-15 | Suven Life Sciences Ltd | Neue indenoä2,1-aüindene und isoindolä2,1-aüindol |
| EP1910321A4 (en) * | 2005-07-05 | 2010-09-01 | Astrazeneca Ab | NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE |
| WO2007050381A2 (en) * | 2005-10-24 | 2007-05-03 | Janssen Pharmaceutica, N.V. | 3-piperidin-4-yl-indole orl-1 receptor modulators |
| EP1984351A1 (en) | 2006-02-17 | 2008-10-29 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| ATE537166T1 (de) * | 2006-10-27 | 2011-12-15 | Boehringer Ingelheim Int | Piperidylpropanthiole als ccr3-modulatoren |
| WO2008049875A1 (en) * | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | Novel substituted piperidyl-propane-thiols |
| CN101553467B (zh) | 2007-01-08 | 2011-12-07 | 苏文生命科学有限公司 | 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途 |
| AU2008246947B2 (en) | 2007-05-03 | 2011-03-31 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands |
| CA2703157C (en) | 2007-10-26 | 2013-02-05 | Suven Life Sciences Limited | Amino arylsulfonamide compounds and their use as 5-ht6 ligands |
| US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
| MX2011002884A (es) | 2008-09-17 | 2011-04-21 | Suven Life Sciences Ltd | Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6. |
| US8563567B2 (en) | 2009-12-30 | 2013-10-22 | Arqule, Inc. | Substituted heterocyclic compounds |
| MX2012007783A (es) | 2010-01-05 | 2012-10-03 | Suven Life Sciences Ltd | Compuestos sulfona que actuan como ligandos del receptor 5-ht6. |
| KR101250606B1 (ko) * | 2011-01-24 | 2013-04-03 | 이화여자대학교 산학협력단 | 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| AU2012321345B2 (en) * | 2011-10-03 | 2016-03-17 | The University Of Utah Research Foundation | Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| EP3082802B1 (en) * | 2013-12-03 | 2020-02-26 | Iomet Pharma Ltd. | Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use |
| AU2015286049B2 (en) | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| WO2016120850A1 (en) * | 2015-01-30 | 2016-08-04 | Pfizer Inc. | Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof |
| EP3331530A4 (en) * | 2015-08-03 | 2018-12-19 | Raze Therapeutics Inc. | Mthfd2 inhibitors and uses thereof |
| CN115521307B (zh) * | 2022-09-30 | 2023-09-22 | 甘肃皓天医药科技有限责任公司 | 一种5-卤代-7-氮杂吲哚的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2124206C (en) * | 1991-11-25 | 2001-02-27 | John Eugene Macor | Indole derivatives |
| US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| DE4444864A1 (de) * | 1994-12-16 | 1996-06-20 | Bayer Ag | Verwendung von 5-Acyl-1,4-dihydropyridinen |
| KR19980703048A (ko) | 1995-03-20 | 1998-09-05 | 피터쥐.스트링거 | 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트 |
| CA2234166A1 (en) | 1995-10-10 | 1997-04-17 | Patric James Hahn | N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists |
| JP2001501946A (ja) | 1996-10-08 | 2001-02-13 | イーライ・リリー・アンド・カンパニー | 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト |
| US6133287A (en) | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
| EP1173432B9 (en) | 1999-04-21 | 2008-10-15 | NPS Allelix Corp. | Piperidine-indole compounds having 5-ht6 affinity |
| AU6339200A (en) | 1999-07-28 | 2001-02-19 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
-
2002
- 2002-01-17 MX MXPA03006605A patent/MXPA03006605A/es active IP Right Grant
- 2002-01-17 ES ES02703087T patent/ES2272667T3/es not_active Expired - Lifetime
- 2002-01-17 EP EP02703087A patent/EP1377580B1/en not_active Expired - Lifetime
- 2002-01-17 JP JP2002561022A patent/JP2004526699A/ja active Pending
- 2002-01-17 WO PCT/US2002/000502 patent/WO2002060871A2/en not_active Ceased
- 2002-01-17 AU AU2002236730A patent/AU2002236730B2/en not_active Ceased
- 2002-01-17 CA CA002433351A patent/CA2433351A1/en not_active Abandoned
- 2002-01-17 AT AT02703087T patent/ATE340795T1/de not_active IP Right Cessation
- 2002-01-17 CN CNB028043480A patent/CN1275967C/zh not_active Expired - Fee Related
- 2002-01-17 DE DE60214990T patent/DE60214990T2/de not_active Expired - Fee Related
- 2002-01-17 BR BR0206595-9A patent/BR0206595A/pt not_active IP Right Cessation
- 2002-01-17 US US10/466,969 patent/US7230011B2/en not_active Expired - Fee Related
-
2007
- 2007-01-18 US US11/624,389 patent/US20070135484A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002060871A3 (en) | 2003-09-12 |
| AU2002236730B2 (en) | 2006-06-15 |
| US7230011B2 (en) | 2007-06-12 |
| ATE340795T1 (de) | 2006-10-15 |
| CA2433351A1 (en) | 2002-08-08 |
| WO2002060871A8 (en) | 2003-12-18 |
| WO2002060871A2 (en) | 2002-08-08 |
| EP1377580A2 (en) | 2004-01-07 |
| DE60214990T2 (de) | 2007-04-05 |
| DE60214990D1 (de) | 2006-11-09 |
| CN1489591A (zh) | 2004-04-14 |
| JP2004526699A (ja) | 2004-09-02 |
| ES2272667T3 (es) | 2007-05-01 |
| US20070135484A1 (en) | 2007-06-14 |
| CN1275967C (zh) | 2006-09-20 |
| US20040102481A1 (en) | 2004-05-27 |
| BR0206595A (pt) | 2004-07-13 |
| EP1377580B1 (en) | 2006-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002060871A3 (en) | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor | |
| HU0400405D0 (en) | Novel compounds | |
| WO2006021213A3 (en) | Vasopressin v1a antagonists | |
| IL185871A0 (en) | N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor | |
| MXPA05012025A (es) | Imidazo y tiazolopiridinas como inhibidores de cinasa jak3. | |
| MXPA03010207A (es) | Nuevas 4-anilinoquinolin-3-carboxamidas. | |
| MXPA05009969A (es) | Metodo para aislar la forma cristalina i de la 5-azacitidina. | |
| CR20140316A (es) | Derivados de indol como antagonistas receptores de s1p1 (divisional 10922) | |
| CY1109854T1 (el) | Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης | |
| IL160915A0 (en) | Indolizines inhibiting kinase proteins | |
| TW200510407A (en) | Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors | |
| GB0127903D0 (en) | Improvements relating to organic compounds | |
| MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
| MXPA05013149A (es) | Derivados de imidazol como antagonistas del receptor de glutamato. | |
| MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
| WO2003027061A3 (en) | Muscarinic agonists | |
| PL376896A1 (pl) | Sposoby wytwarzania 5-androstenów podstawionych w pozycji C-7 | |
| DE602004012146D1 (en) | Pyrazolopyrimidine | |
| NO20022977D0 (no) | Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter | |
| DK1742950T3 (da) | Pyrazolo-[4,3-D]-pyrimidiner | |
| TR200200494T2 (tr) | Yağlı asit sintazı inhibitörleri. | |
| GB0215392D0 (en) | Chemical compounds | |
| MXPA04005988A (es) | 3,4-dihidro-1h-isoquinolin-2-il-derivados. | |
| MY140858A (en) | Ampa receptor potentiators | |
| TW200640870A (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |